Oxidation of low-density lipoprotein and atherosclerosis in chronic renal failure

Medical Hypotheses

Volumn 49, Issue 5, 1997, Pages 389-395

  Hasselwander, O ^a   Young, I S ^a,b  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b ROYAL VICTORIA HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

LIPOPROTEIN; LOW DENSITY LIPOPROTEIN;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY FAILURE; HUMAN; KIDNEY FAILURE; LIPID PEROXIDATION; OXIDATION; PRIORITY JOURNAL; REVIEW;

EID: 0030669124     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-9877(97)90084-0     Document Type: Article

References (68)

1. Lindner A, Charra B, Sherrard D J, Scribner B H. Accelerated atherosclerosis in prolonged maintenance haemodialysis. N Engl J Med 1974; 290: 697-701.
2. Raine A E G, MacMohan S H, Selwood N H, Wing A J, Brunner F P. Mortality from myocardial infarction in patients on renal replacement therapy. Nephrol Dial Transplant 1991; 6: 902.
3. Witztum J L, Steinberg D. Role of oxidised low density lipoprotein in atherogenesis. J Clin Invest 1991; 88: 1785-1792.
4. Witztum J L. Susceptibility of low-density lipoprotein to oxidative modification. Am J Med 1993; 94: 347-356.
5. Reaven P D, Witztum J L. The role of oxidation of LDL in atherogenesis. Endocrinologist 1995; 5: 44-54.
6. Maggi E, Bellazzi R, Gazo A, Seccia M, Bellomo G. Autoantibodies against oxidatively-modified LDL in uremic patients undergoing dialysis. Kidney Int 1994; 46: 869-876.
7. Loughrey C M, Young I S, McDowell I, McNamee P, Trimble E R. Resistance of LDL cholesterol from patients receiving haemodialysis for end-stage renal failure to in vitro oxidation. Atherosclerosis 1994; 110: 185-193.
8. Sutherland W H F, Walker R J, Ball M J, Stapley S A, Robertson M C. Oxidation of low density lipoproteins from patients with renal failure or renal transplants. Kidney Int 1995; 48: 227-236.
9. Schulz T, Schiffl H, Scheithe R, Hrboticky N, Lorenz R. Preserved antioxidative defense of lipoproteins in renal failure and during hemodialysis. Am J Kidney Dis 1995; 25: 564-571.
10. Esterbauer H, Gebicki J, Puhl H, Jurgens G. The role of lipid peroxidation and antioxidants in oxidative modification of LDL. Free Radic Biol Med 1992; 13: 341-390.
11. O'Leary V J, Darley-Usmar V M, Russell J, Stone D. Prooxidant effects of lipoxygenase-derived peroxides on the Copper-initiated oxidation of low-density lipoprotein. Biochem J 1992; 282: 631-634.
12. Smith C, Mitchinson M, Aruoma O I, Halliwell B. Stimulation of lipid peroxidation and hydroxyl-radical generation by the contents of human atherosclerotic lesions. Biochem J 1992; 286: 901-905.
13. Roselaar S E, Nazhat N B, Winyard P G, Tone P, Cunningham J, Blake DR. Detection of oxidants in uremic plasma by electron spin resonance spectroscopy. Kidney Int 1995; 48: 199-206.
14. Maher E R, Wickens D G, Griffin J F A, Kyle P, Curtis J R, Dormandy T L. Neutropenia and plasma free radical products during haemodialysis. Nephrol Dial Trans 1988; 3: 277-283.
15. Schmidtmann S, Baehr R, Precht K. Free radicals induce increased lysis of red blood cells after haemodialysis. Nephrol Dial Trans 1990; 5: 600-603.
16. Nguyen A T, Lethias C, Zingraff J, Herbelin A, Naret C, Descamps-Latscha B. Haemodialysis membrane-induced activation of phagocyte oxidative metabolism detected in vivo and in vitro with microamounts of whole blood. Kidney Int 1985; 28: 158-167.
17. Ranjadayalan K, Umachandran V, Davies S W, Syndercombe-Court D, Gutteridge C N, Timmis A D. Thrombolytic treatment in acute myocardial infarction: neutrophil activation, peripheral leucocyte responses, and myocardial injury. Br Heart J 1991; 66: 10-14.
18. Pronai L, Hiramatsu K, Saigusa Y, Nakazawa H. Low superoxide scavenging activity associated with enhanced superoxide generation by monocytes from male hypertriglyceridaemia patients with and without diabetes. Atherosclerosis 1991; 90: 39-47.
19. Lyons T J. Oxidised low density lipoproteins: a role in the pathogenesis of atherosclerosis in diabetes? Diabetic Med 1991; 8: 411-419.
20. Wolff S P, Jiang Z Y, Hunt J V. Protein glycation and oxidative stress in diabetes mellitus and ageing. Free Radic Biol Med 1991; 10: 339-352.
21. Gugliucci A, Bendayan M. Renal fate of circulating advanced glycated end-products (age)-evidence for reabsorption and catabolism of age-peptides by renal proximal tubular cells. Diabetologia 1996; 39: 149-160.
22. Andany M A. Is atherosclerosis equivalent to cholesterol. Nephron 1995; 7: 487-488.
23. Parthasarathy S. Oxidation of low-density lipoprotein by thiol compounds leads to its recognition by the acetyl LDL receptor. Biochim Biophys Acta 1987; 917: 337-340.
24. Peuchant E, Carbonneau M-A, Dubourg L et al. Lipoperoxidation in plasma and red blood cells of patients undergoing haemodialysis: vitamins A, E, and iron status. Free Radic Biol Med 1994; 16: 339-346.
25. Loughrey C M, Young I S, Lightbody J H, McMaster D, McNamee P T, Trimble E R. Oxidative stress in hemodialysis. Q J Med 1994; 87: 679-683.
26. Jackson P, Loughrey C M, Lightbody J H, McNamee P T, Young I S. Effect of hemodialysis on total antioxidant capacity and serum antioxidants in patients with chronic-renal-failure. Clin Chem 1995; 41: 1135-1138.
27. Kopple J D, Swendseid M E. Vitamin nutrition in patients undergoing maintenance hemodialysis. Kidney Int 1975; 7s: 579-584.
28. van den Berg J J M, Kuypers F A, Roelofsen B, Op den Kamp J A F. The cooperative action of vitamins E and C in the protection against peroxidation of parinaric acid in human erythrocyte membranes. Chem Phys Lipids 1990; 53: 309-320.
29. Wilke B C, Vidaihet M, Favier A et al. Selenium, glutathione-peroxidase (Gsh-Px) and lipid-peroxidation products before and after selenium supplementation. Clin Chim Acta 1992; 207: 137-142.
30. Roxborough H E, Young I S. Carbamylation of proteins and atherogenesis in renal failure. Med Hypotheses 1995; 45: 125-128.
31. Stim J, Shaykh M, Anwar F, Ansari A, Arruda J A L, Dunea G. Factors determining hemoglobin carbamylation in renal-failure. Kidney Int 1995; 48: 1605-1610.
32. Dengler T J, Robertz-Vaupel G M, Dengler H J. Albumin binding in uremia: quantitative assessment of inhibition by endogenous ligands and carbamylation of albumin. Eur J Clin Pharmacol 1992; 43: 491-499.
33. Roxborough H E, Millar C A, McEneny J, Young I S. Carbamylation inhibits the ferroxidase activity of ceruloplasmin. Biochem Biophys Res Commun 1995; 214: 1073-1078.
34. Winyard P G, Hider R C, Brailsford S, Drake A F, Lunec J, Blake D R. Effects of oxidative stress on some physicochemical properties of ceruloplasmin. Biochem J 1989; 258: 435-445.
35. Attman P O, Samuelsson O, Alaupovic P. Lipoprotein metabolism and renal failure. Am J Kidney Dis 1993; 21: 573-592.
36. Horkko S, Huttunen K, Kesaniemi Y A. Decreased clearance of low-density lipoprotein in uremic patients under dialysis treatment. Kidney Int 1995; 47: 1732-1740.
37. Liu M, Krul E S, Subbaiah P V. Effect of apoprotein-b conformation on the activation of lysolecithin acyltransferase and lecithin-cholesterol acyltransferase-studies with subfractions of low-density lipoproteins. J Biol Chem 1992; 267(8): 5139-5147.
38. Horkko S, Savolainen M J, Kervinen K, Kesaniemi Y A. Carbamylation-induced alterations in low-density lipoprotein metabolism. Kidney Int 1992; 41: 1175-1181.
39. Appel G. Lipid abnormalities in renal disease. Kidney Int 1991; 39: 169-183.
40. Short C D, Durrington P N. Hyperlipidaemia and renal disease. Baillieres Clin Endocrinol Metab 1990; 4: 777-806.
41. Skinner E R, Wilson H M. High-density lipoprotein subfractions and cardiovascular disease. Biochem Soc Trans 1990; 18: 1074-1076.
42. Hahn R, Oette K, Mondorf H, Finke K, Sieberth H G. Analysis of cardiovascular risk-factors in chronic-hemodialysis patients with special attention to the hyperlipoproteinemias. Atherosclerosis 1983; 48: 279-288.
43. Mackness M I, Mackness B, Durrington P N, Connelly P W, Hegele R A. Paraoxonase - biochemistry, genetics and relationship to plasma-lipoproteins. Curr Opin Lipid 1996; 7: 69-76.
44. Klimov A N, Nikiforova A A, Pleskov V M, Kuzmin A A, Kalashnikova N N, Antipova T O. The protective action of high-density lipoproteins, their subfractions, and lecithin-cholesterol acetyltransferase in the peroxide modification of low-density lipoproteins. Biochemistry USSR 1989; 54: 93-97.
45. Parthasarathy S, Barnett J, Fong L G. High-density-lipoprotein inhibits the oxidative modification of low-density-lipoprotein. Biochim Biophys Acta 1990; 1044: 275-283.
46. 2+-catalyzed oxidation of human low-density lipoprotein. FEBS Lett 1989; 257: 435-438.
47. Mackness M I, Arrol S, Abbott C, Durrington P N. Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis 1993; 104: 129-135.
48. Tribble D L, Chu B M, Gong E L, Vanvenrooij F, Nichols AV. HDL antioxidant effects as assessed using a non-exchangeable probe to monitor particle-specific peroxidative stress in LDL-HDL mixtures. J Lipid Res 1995; 36: 2580-2589.
49. Klimov A N, Gurevich V S, Nikiforova A A et al. Antioxidative activity of high-density lipoproteins in vivo. Atherosclerosis 1993; 100: 13-18.
50. Mackness M I, Abbott C, Durrington P N, Arrol S. The role of high-density lipoprotein in lipid-soluble antioxidant vitamins in inhibiting low-density lipoprotein oxidation. Biochem J 1993; 294: 829-834.
51. Henriksen T, Evensen S A, Carlander B. Injury to cultured endothelial cells induced by low density lipoproteins: protection by high density lipoproteins. Scand J Clin Lab Invest 1979; 39: 369-375.
52. Navab M, Imes S S, Hama S Y et al. Monocyte transmigration induced by modification of low-density lipoprotein in cocultures of human aortic-wall cells is due to induction of monocyte chemotactic protein-1 synthesis and is abolished by high-density lipoprotein. J Clin Invest 1991; 88(6): 2039-2046.
53. Zwijsen R M L, Dehaan L H J, Kuivenhoven J A, Nusselder I C J. Modulation of low-density lipoprotein-induced inhibition of intercellular communication by antioxidants and high-density lipoproteins. Food Chem Toxicol 1991; 29: 615-620.
54. Schmidt K, Klatt P, Graier W F, Kostner G M, Kukovertz W R. High-density lipoprotein antagonizes the inhibitory effects of oxidized low-density lipoprotein and lysolecithin on soluble guanylyl cyclase. Biochem Biophys Res Commun 1992; 182: 302-308.
55. Mehta J L, Bryant J L, Mehta P. Reduction of nitric-oxide synthase activity in human neutrophils by oxidized low-density lipoproteins - reversal of the effect of oxidized low-density lipoproteins by high-density lipoproteins and L-arginine. Biochem Pharmacol 1995; 50: 1181-1185.
56. Kunitake S T, Jarvis M R, Hamilton R L, Kane J P. Binding of transition metals by apolipoprotein A-I-containing plasma-lipoproteins - inhibition of oxidation of low-density lipoproteins. Proc Natl Acad Sci USA 1992; 89: 6993-6997.
57. Decossin C, Tailleux A, Fruchart J C, Fievet C. Prevention of in vitro low-density lipoprotein oxidation by an albumin-containing Lp A-I subfraction. Biochim Biophys Acta 1995; 1255: 31-38.
58. Sattler W, Christison J, Stocker R, Cholesterylester hydroperoxide reducing activity associated with isolated high-density and low-density lipoproteins. Free Radic Biol Med 1995; 18: 421-429.
59. Watson A D, Berliner J A, Hama S Y et al. Protective effect of high-density lipoprotein associated paraoxonase - inhibition of the biological-activity of minimal oxidized low-density lipoprotein. J Clin Invest 1995; 96: 2882-2891.
60. Watson A D, Navab M, Hama S Y et al. Effect of platelet-activating factor acetylhydrolase on the formation and action of minimally oxidized low-density lipoprotein. J Clin Invest 1995; 95: 774-782.
61. Christison J K, Rye K A, Stocker R. Exchange of oxidized cholesteryl linoleate between LDL and HDL mediated by cholesteryl ester transfer protein. J Lipid Res 1995; 36: 2017-2026.
62. Bowry V W, Stanley K K, Stocker R. High-density-lipoprotein is the major carrier of lipid hydroperoxides in human blood-plasma from fasting donors. Proc Natl Acad Sci USA 1992; 89: 10316-10320.
63. Sattler W S, Stocker R. Greater selective uptake by Hep G2 cells of high-density lipoprotein cholesteryl ester hydroperoxides than of unoxidised cholesteryl esters. Biochem J 1993; 294: 771-778.
64. Joven J, Vilella E, Ahmad S, Cheung M C, Brunzell J D. Lipoprotein heterogeneity in end-stage renal-disease. Kidney Int 1993; 43: 410-418.
65. Chan M K, Varghese Z, Moorhead J F. Lipid abnormalities in uremia, dialysis and transplantation. Kidney Int 1981; 19: 625-637.
66. Chait A, Brazg R L, Tribble D L, Krauss R M. Susceptibility of small, dense, low-density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern-B. Am J Med 1993; 94: 350-356.
67. Loughrey C M, Young I S, McEneny J, McNamee P T, Trimble E R. Oxidation of VLDL cholesterol in hemodialysis-patients. J Am Soc Nephrol 1994; 5: 497.
68. Nagano Y, Arai H, Kita T. High-density lipoprotein loses its effect to stimulate efflux from foam cells after oxidative modification. Proc Natl Acad Sci USA 1991; 88: 6457-6461.